Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe G, Ciccarelli G, Soldovieri L, Capece U, Cefalo CMA, Moffa S, Nista EC, Brunetti M, Cinti F, Gasbarrini A, Pontecorvi A, Giaccari A, Mezza T. Di Giuseppe G, et al. Among authors: giaccari a. Trends Endocrinol Metab. 2023 Apr;34(4):216-230. doi: 10.1016/j.tem.2023.02.001. Epub 2023 Feb 27. Trends Endocrinol Metab. 2023. PMID: 36858875 Free article. Review.
Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes.
Di Giuseppe G, Soldovieri L, Ciccarelli G, Ferraro PM, Quero G, Cinti F, Capece U, Moffa S, Nista EC, Gasbarrini A, Mari A, Alfieri S, Tondolo V, Pontecorvi A, Holst JJ, Giaccari A, Mezza T. Di Giuseppe G, et al. Among authors: giaccari a. J Clin Invest. 2024 Mar 12;134(8):e175133. doi: 10.1172/JCI175133. J Clin Invest. 2024. PMID: 38470487 Free PMC article. No abstract available.
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C; LIPIGEN Group and the LIPIGEN Paediatric Group. Casula M, et al. Atherosclerosis. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231. Epub 2023 Aug 12. Atherosclerosis. 2023. PMID: 37648636 Free article.
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy].
Arca M, Averna M, Borghi C, Lettino M, Perrone Filardi P, Alberti A, Bilato C, Calabrò P, Carubbi F, Ciccone MM, Cipollone F, Citroni N, De Luca L, Giaccari A, Iannuzzo G, Maloberti A, Marcucci R, Pignatelli Spinazzola P, Pirro M, Pisciotta L, Sarullo F, Sciacqua A, Suppressa P, Varbella F, Werba JP, Zambon A. Arca M, et al. Among authors: giaccari a. G Ital Cardiol (Rome). 2023 Oct;24(10):770-780. doi: 10.1714/4100.40977. G Ital Cardiol (Rome). 2023. PMID: 37767829 Review. Italian.
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, Monami M; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Mannucci E, et al. Among authors: giaccari a. Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2745-2755. doi: 10.1016/j.numecd.2021.06.002. Epub 2021 Jul 5. Nutr Metab Cardiovasc Dis. 2021. PMID: 34364771 Free article.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; GLIMPLES study investigators. Fadini GP, et al. Among authors: giaccari a. Diabetes Obes Metab. 2024 Jun;26(6):2390-2400. doi: 10.1111/dom.15554. Epub 2024 Mar 13. Diabetes Obes Metab. 2024. PMID: 38477183
Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
Bonora BM, Russo G, Leonetti F, Strazzabosco M, Nollino L, Aimaretti G, Giaccari A, Broglio F, Consoli A, Avogaro A, Fadini GP; GLIMPLES Study Investigators. Bonora BM, et al. Among authors: giaccari a. J Endocrinol Invest. 2024 Feb 18. doi: 10.1007/s40618-024-02309-2. Online ahead of print. J Endocrinol Invest. 2024. PMID: 38369592
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
159 results